An analyst call over the Aduhelm coverage debacle sees Biogen threaten more cost cutting.
The US Centers for Medicare & Medicaid Services’ national coverage determination for Biogen’s Aduhelm makes for uncomfortable reading.
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
A handful of huge success stories mask disappointing performances elsewhere, with small caps and Asian pharma firms feeling the pain.
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Could Aduhelm be pulled? Will Incyte get acquired? Here are some of your wildest New Year predictions.
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
Explore what might be in store for biopharma next year in our new report, with new data analyses, catalyst tables and investor interviews.